# Grand Pharma invests $12M in CoRISMA for heart failure device rights

Grand Pharmaceutical Group (远大医药) has entered a strategic partnership with CoRISMA MCS Systems, investing $12 million for a 22.2% stake and exclusive rights to develop and commercialize CoRISMA's heart failure treatment systems in Greater China and several Southeast Asian countries.

- Type: Partnership
- Announced: 2021-08-05
- Value: $12.0M
- Status: announced
- Products: heart failure treatment systems (CoRISMA series)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Grand Pharmaceutical Group](https://endata.com/companies/28076.md) (investor)
- [CoRISMA MCS Systems, Inc](https://endata.com/companies/56909.md) (partner)

## Sources

- [beta.zhitongcaijing.com](http://beta.zhitongcaijing.com/content/detail/528076.html), 2021-08-05: "该集团将以1200万美元为代价取得CoRISMA约22.2%的股权，后续会进一步投入以获得治疗心力衰竭的创新医疗器械CoRISMA系列产品在大中华区的独家开发、生产及商业化权益。"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.